IN THE CLAIMS

Please amend the claims as follows:

Claims 1-8 (Canceled).

9. (Currently Amended): A method for alleviating a symptom from lipopolysaccharide-induced inflammation comprising protectively administering to a person orally or parenterally an effective amount of human-type lactoferrin for a time and under conditions effective to alleviate said symptom, wherein said symptom is accumulation of body fluid containing albumin at the inflammatory site.

10. (Previously Presented): The method according to claim 9, wherein the effective amount is 0.1 to 20 mg/kg of body weight/day in intravenous injection.

11. (Previously Presented): The method according to claim 10, wherein the effective amount is 0.5 to 10 mg/kg of body weight/day.

12. (Previously Presented): The method according to claim 9, wherein the effective amount is 1 to 200 mg/kg of body weight/day in intraperitoneal administration.

13. (Previously Presented): The method according to claim 9, wherein the effective amount is 5 to 1000 mg/kg of body weight/day in oral administration.

14. (Previously Presented): The method according to claim 13, wherein the effective amount is 20 to 1000 mg/kg of body weight/day.

15. (Currently Amended): A method for alleviating a symptom from lipopolysaccharide-induced inflammation comprising protectively administering to a person orally or parenterally an effective amount of human-type lactoferrin for a time and under conditions effective to alleviate said symptom, wherein said symptom is accumulation of albumin at the inflammatory site.

16. (Previously Presented): The method according to claim 15, wherein the effective amount is 0.1 to 20 mg/kg of body weight/day in intravenous injection.

17. (Previously Presented): The method according to claim 16, wherein the effective amount is 0.5 to 10 mg/kg of body weight/day.

18. (Previously Presented): The method according to claim 15, wherein the effective amount is 1 to 200 mg/kg of body weight/day in intraperitoneal administration.

19. (Previously Presented): The method according to claim 15, wherein the effective amount is 5 to 1000 mg/kg of body weight/day in oral administration.

20. (Previously Presented): The method according to claim 19, wherein the effective amount is 20 to 1000 mg/kg of body weight/day.

21. (Currently Amended): A method for alleviating a symptom from lipopolysaccharide-induced inflammation comprising protectively administering to a person orally or parenterally an effective amount of human-type lactoferrin for a time and under conditions effective to alleviate said symptom, wherein said symptom is decrease of albumin concentration in blood.

22. (Previously Presented): The method according to claim 21, wherein the effective amount is 0.1 to 20 mg/kg of body weight/day in intravenous injection.

23. (Previously Presented): The method according to claim 22, wherein the effective amount is 0.5 to 10 mg/kg of body weight/day.

24. (Previously Presented): The method according to claim 21, wherein the effective amount is 1 to 200 mg/kg of body weight/day in intraperitoneal administration.

25. (Previously Presented): The method according to claim 21, wherein the effective amount is 5 to 1000 mg/kg of body weight/day in oral administration.

26. (Previously Presented): The method according to claim 25, wherein the effective amount is 20 to 1000 mg/kg of body weight/day.

Claim 27 (Currently Amended): A method for alleviating a symptom from lipopolysaccharide-induced inflammation comprising protectively administering to a person orally or parenterally an effective amount of human-type lactoferrin for a time and under conditions effective to alleviate said symptom, wherein said symptom is increase of neutrophils in blood.

28. (Previously Presented): The method according to claim 27, wherein the effective amount is 0.1 to 20 mg/kg of body weight/day in intravenous injection.

29. (Previously Presented): The method according to claim 28, wherein the effective amount is 0.5 to 10 mg/kg of body weight/day.

30. (Previously Presented): The method according to claim 27, wherein the effective amount is 1 to 200 mg/kg of body weight/day in intraperitoneal administration.

31. (Previously Presented): The method according to claim 27, wherein the effective amount is 5 to 1000 mg/kg of body weight/day in oral administration.

32. (Previously Presented): The method according to claim 31, wherein the effective amount is 20 to 1000 mg/kg of body weight/day.

SUPPORT FOR THE AMENDMENTS

The amendments to Claims 9, 15, 21 and 27 are supported by the Examples set forth in the specification. No new matter is believed to have been added to the present application by the amendments submitted above.